Drug Profile
Research programme: allergy immunotherapies - DMS Imaging
Alternative Names: rag-ASIT+™Latest Information Update: 29 Jun 2022
Price :
$50
*
At a glance
- Originator ASIT biotech
- Developer DMS Imaging
- Class Allergy immunotherapies; Peptides
- Mechanism of Action Immunomodulators; T lymphocyte modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes - Food hypersensitivity; Ragweed pollen hypersensitivity
Highest Development Phases
- No development reported Food hypersensitivity; Ragweed pollen hypersensitivity
Most Recent Events
- 28 Oct 2021 No recent reports of development identified for preclinical development in Ragweed pollen hypersensitivity in Belgium (SC)
- 28 Sep 2020 No recent reports of development identified for research development in Food-hypersensitivity in Belgium (SC)
- 05 Nov 2018 Research programme: allergy immunotherapies - ASIT biotech is available for licensing as of 05 Nov 2018. www.asitbiotech.com 9253616